MK
Madhu Kumar Goldman Sachs Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Jazz Pharmaceuticals
JAZZ
$7.77B
| $128.02 | $185 |
45%
upside
| Buy | 6 days ago |
|
2
Fulcrum Therapeutics
FULC
$372M
| $6.88 | $6 |
13%
downside
| Neutral | 1 year ago |
|
3
Informatica
INFA
$7.55B
| $24.78 | $26 |
5%
upside
| Neutral | 1 year ago |
|
4
Utz Brands
UTZ
$1.18B
| $13.65 | $17 |
25%
upside
| Neutral | 1 year ago |
|
5
Alector
ALEC
$285M
| $2.82 | $4 |
42%
upside
| Sell | 1 year ago |
|
6
Krystal Biotech
KRYS
$4.33B
| $149.75 | $155 |
4%
upside
| Buy | 2 years ago |
|
7
Cytokinetics
CYTK
$5.95B
| $49.75 | $53 |
7%
upside
| Buy | 2 years ago |
|
8
Arrowhead Research
ARWR
$3.87B
| $28 | $73 |
161%
upside
| Buy | 2 years ago |
|
9
Apellis Pharmaceuticals
APLS
$3.62B
| $28.65 | $141 |
392%
upside
| Buy | 2 years ago |
|
10
Syndax Pharmaceuticals
SNDX
$1.39B
| $16.19 | $34 |
110%
upside
| Buy | 2 years ago |
|
11
Iovance Biotherapeutics
IOVA
$796M
| $2.20 | $6 |
173%
upside
| Neutral | 2 years ago |
|
|
12
Iovance Biotherapeutics
IOVA
$796M
| $2.20 | $6 |
173%
upside
| Neutral | 2 years ago |
|
13
Arcturus Therapeutics
ARCT
$455M
| $16.76 | $14 |
16%
downside
| Sell | 2 years ago |
|
14
Dynavax Technologies
DVAX
$1.17B
| $9.98 | $21 |
110%
upside
| Buy | 2 years ago |
|
15
Edgewise Therapeutics
EWTX
$1.54B
| $14.62 | $5 |
66%
downside
| Sell | 3 years ago |
|
16
Arvinas
ARVN
$559M
| $7.61 | $89 |
1,070%
upside
| Buy | 3 years ago |
|
17
Intellia Therapeutics
NTLA
$1.25B
| $11.62 | $85 |
632%
upside
| Neutral | 4 years ago |
|
|
CLLS
18
Cellectis
CLLS
$264M
| $2.63 | $39 |
1,383%
upside
| Outperform | 4 years ago |
|
|
19
Arcturus Therapeutics
ARCT
$455M
| $16.76 | $69 |
312%
upside
| Neutral | 4 years ago |
|
20
uniQure
QURE
$973M
| $17.73 | $57 |
221%
upside
| Outperform | 5 years ago |
|
21
Vir Biotechnology
VIR
$714M
| $5.14 | $20 |
289%
upside
| Underperform | 5 years ago |
|
22
Scholar Rock
SRRK
$3.12B
| $32.44 | $35 |
8%
upside
| Outperform | 5 years ago |
|
23
Arbutus Biopharma
ABUS
$753M
| $4.01 | $6 |
50%
upside
| Buy | 5 years ago |
|